TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30307129
Drug: 10 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 or 8-mm long implants
Study: 30307129
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants in augmented bone
Study: 26721935
Drug: Eldelumab 25
Normalized name: Eldelumab
DrugBank: Eldelumab (DB06116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldelumab 25 mg/kg
Study: 26721935
Drug: Eldelumab 15
Normalized name: Eldelumab
DrugBank: Eldelumab (DB06116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldelumab 15 mg/kg
Study: 22060048
Drug: Maxillary sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary sinus floor augmentation surgery
Study: 20594588
Drug: Secondary measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary measures favoring intensive therapy
Study: 18854722
Drug: Fluoxetine (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-60 mg by mouth per day)
Study: 12242602
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg for 2 days, then 30 mg for 5 days) plus phenytoin (200 mg daily for 17 days)
Study: 12242602
Drug: Phenytoin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (200 mg daily from day 8 to day 17) plus mirtazapine (15 mg for 2 days, then 30 mg for 15 days)
Study: 12242602
Drug: Phenytoin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (200 mg daily)
Study: 10080828
Drug: rhIFN-gamma injections
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIFN-gamma injections paired with PG
Study: 10080828
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline injections paired with PG
Study: 10080828
Drug: rhIFN-gamma injections
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIFN-gamma injections alone
Study: 7653318
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum (0 pieces per day)
Study: 7653318
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum (7 pieces per day)
Study: 7653318
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum (15 pieces per day)
Study: 7653318
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum (30 pieces per day)
Study: 344341
Drug: Immunofluorescence‐nDNA antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunofluorescence‐nDNA antibody test system
Study: 28934837
Drug: 1W bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1W bromocriptine treatment (2.5 mg for 7 days)
Study: 28934837
Drug: 8W bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8W bromocriptine treatment (5 mg for 2 weeks followed by 2.5 mg for 6 weeks)
Study: 28934837
Drug: 1W bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1W bromocriptine treatment
Study: 28934837
Drug: 8W bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8W bromocriptine treatment
Study: 25238025
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (RE) 100, 250, 500 or 1000 mg once daily or 250 mg twice daily
Study: 25238025
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone once daily
Study: 20878572
Drug: Paclitaxel combined
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy every two weeks in each cycle
Study: 20878572
Drug: Paclitaxel combined
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy
Study: 20878572
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received surgery within 2 weeks and postoperative chemotherapy of 6 cycles of paclitaxel combined with FOLFOX4 regimen
Study: 12802023
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg weekly injections
Study: 12802023
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert oil) weekly injections
Study: 1891485
Drug: Alprazolam (1.48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.48 mg daily)
Study: 1891485
Drug: Oxazepam (44.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (44.4 mg daily)
Study: 6576616
Drug: Short-term psychotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychotherapy (one-hour weekly sessions for a maximum of ten sessions)
Study: 6576616
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only (control group)
Study: 30198775
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron isomaltoside (IVI)
Study: 22923433
Drug: Everolimus (mTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (mTOR inhibitor)
Study: 8988412
Drug: Azithromycin (AZM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (AZM), 100 mg capsules or 10% fine granules, given orally
Study: 8988412
Drug: Azithromycin (AZM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (AZM), 8.3 mg/kg once daily for 3 days
Study: 8988412
Drug: Azithromycin (AZM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (AZM), 12.5 mg/kg once daily for 3 days
Study: 1617930
Drug: roxithromycin (ROX)
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (ROX) 150 mg b.i.d. orally (n = 244)
Study: 1617930
Drug: amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin plus clavulanic acid (AMX + CA) 500 mg AMX + 125 mg CA t.i.d. orally (n = 246)
Study: 1617930
Drug: amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin plus clavulanic acid (AMX + CA)
Study: 6398125
Drug: Fosfomycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin plus amoxicillin (CFL)
Study: 30084900
Drug: Silicone cream
Normalized name: REMEDY SILICONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone cream
Study: 26308179
Drug: Carn‐BA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carn‐BA (2 g of L‐carnosine and 2 g of β‐alanine)
Study: 12829905
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis for spontaneous bacterial peritonitis
Study: 12829905
Drug: Prior antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior antifungal prophylaxis
Study: 11214766
Drug: tiopronin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiopronin (200 mg/day) for 14 days
Study: 11214766
Drug: tiopronin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiopronin (500 mg/day) for 14 days
Study: 11214766
Drug: bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine (5 mg/day) for 14 days
Study: 11214766
Drug: conservative measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: conservative measures (no medication)
Study: 11214766
Drug: tiopronin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiopronin (200 mg/day)
Study: 11214766
Drug: tiopronin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiopronin (500 mg/day)
Study: 11214766
Drug: bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine (5 mg/day)
Study: 11214766
Drug: tiopronin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiopronin (200 mg/day) and bromocriptine
Study: 1670746
Drug: Doxazosin (11.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (11.9 +/- 0.9 mg daily)
Study: 30698554
Drug: Recognan (citicoline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recognan (citicoline) 500 mg (5 ml) orally for 30 days
Study: 26690861
Drug: Electronic Personal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic Personal Administration of Cognitive Therapy (ePACT)
Study: 22424000
Drug: Intravenous glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose, insulin, and potassium (GIK) administered prehospital by paramedics
Study: 22424000
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered prehospital by paramedics
Study: 11873008
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg), one tablet twice daily from 36-38 weeks' gestation until delivery, then for 7 more days in DITRAME only
Study: 11873008
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one tablet twice daily from 36-38 weeks' gestation until delivery, then for 7 more days in DITRAME only
Study: 11873008
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg) among women with CD4 cell counts < 500/ml
Study: 11873008
Drug: Placebo among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo among women with CD4 cell counts < 500/ml
Study: 11873008
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg) among women with CD4 cell counts >= 500/ml
Study: 11873008
Drug: Placebo among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo among women with CD4 cell counts >= 500/ml
Study: 9864079
Drug: Buspirone (20‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (20‐30 mg/day) added to selective serotonin reuptake inhibitors (SSRIs)
Study: 9864079
Drug: Buspirone (20‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (20‐30 mg/day) added to clomipramine
Study: 9864079
Drug: Buspirone augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone augmentation therapy
Study: 8680900
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day mesalazine
Study: 8680900
Drug: 3.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/day mesalazine
Study: 2220604
Drug: Enalapril (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (daily doses ranged from 2.5 to 40 mg)
Study: 477676
Drug: Levamisole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months)
Study: 477676
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months)
Study: 21827664
Drug: Black sesame
Normalized name: ROSEMARY OIL 5 g in 100 g TOPICAL CREAM [GZE Black Sesame Rosemary Keratin HairMask]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black sesame meal (2.52 g capsules daily for 4 weeks)
Study: 21827664
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (daily for 4 weeks)
Study: 9782219
Drug: Short-term prophylaxis
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 15 days)
Study: 9782219
Drug: Long-term prophylaxis
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 30 days)
Study: 3410606
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg i.v. methylepoxyproscillaridin (P35)
Study: 3410606
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral methylepoxyproscillaridin (P35)
Study: 30630108
Drug: Monthly newsletter
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly newsletter (control)
Study: 28727701
Drug: Blinded placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded placebo shockwave treatment
Study: 28727701
Drug: Unblinded placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unblinded placebo shockwave treatment
Study: 23153437
Drug: PlyD1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PlyD1 at 10 μg
Study: 23153437
Drug: PlyD1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PlyD1 at 25 μg
Study: 23153437
Drug: PlyD1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PlyD1 at 50 μg
Study: 16488376
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg glatiramer acetate
Study: 16488376
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glatiramer acetate
Study: 29750366
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (2 g daily oral dose)
Study: 27358385
Drug: Palonosetron (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.75 mg)
Study: 10737366
Drug: Preoperative pentoxifiline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative pentoxifiline (PTFL) administration
Study: 9189781
Drug: Flavored, 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored, 6% sucrose drink containing 25 mmol/L NaCl (LNa(+)‐R)
Study: 9189781
Drug: Flavored, 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored, 6% sucrose drink containing 50 mmol/L NaCl (HNa(+)‐R)
Study: 3872836
Drug: Carprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (300 mg/day)
Study: 29150850
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg/d)
Study: 29150850
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 mg/d)
Study: 20097780
Drug: Collaborative depression
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative depression care (problem-solving therapy and/or antidepressant medication, telephone follow-up, systems navigation assistance)
Study: 12576246
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of mifepristone
Study: 12576246
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of mifepristone
Study: 10382880
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 400 mg moxifloxacin
Study: 10382880
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 400 mg moxifloxacin
Study: 21816681
Drug: 2-year multilevel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-year multilevel intervention with monthly on-site consultation from expert nurses
Study: 21816681
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control with monthly information about aging and physical assessment of elders
Study: 17919894
Drug: Pioglitazone (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-30 mg/day) added to metformin or sulphonylurea
Study: 17919894
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of metformin (400mg) and glibenclamide (2.5 mg)
Study: 12809818
Drug: Medical (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical (ranitidine 150 mg t.i.d.)
Study: 12809818
Drug: Control (antacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antacids as needed)
Study: 3926614
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide dinitrate in sustained-release form (sustained-release ISDN)
Study: 3926614
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide 5-mononitrate (IS 5-MN)
Study: 3926614
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg buccal nitroglycerin in sustained-release form (NTGB)
Study: 3926614
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg oral nitroglycerin in sustained-release form (NTGO)
Study: 29636305
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (5% of MIP) for 6 weeks
Study: 27821107
Drug: Electro-acupuncture treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture treatments
Study: 22480187
Drug: Moderate insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate insulin therapy (MIT) with glucose target 120 to 140 mg/dl
Study: 22480187
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (CIT) with glucose target 180 to 200 mg/dl
Study: 20678878
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day plus ASA 75 to 100 mg/day
Study: 20678878
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus ASA 75 to 100 mg/day
Study: 8777101
Drug: Diltiazem 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 0.2 mg kg‐1
Study: 8777101
Drug: Verapamil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 0.1 mg kg‐1
Study: 2051002
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate 400 mg per day
Study: 6881428
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solutions (ORS) containing 90 mmol/liter of sodium
Study: 6881428
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solutions (ORS) containing 50 mmol/liter of sodium
Study: 30075736
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 weekly for five courses
Study: 30075736
Drug: Two to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two to four cycles of TP (Taxol 135 mg/m2, D1, and DDP 75 mg/m2, D1‐3) sequential chemotherapy
Study: 24904748
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy combined with spinal manipulation
Study: 18480682
Drug: Peony‐Glycyrrhiza Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peony‐Glycyrrhiza Decoction (PGD) 45 g/d
Study: 18480682
Drug: Bromocriptine (BMT)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BMT) 5 mg/d
Study: 16316784
Drug: Pulse steroid
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse steroid therapy
Study: 16316784
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose steroid treatment
Study: 14627912
Drug: Steroid-free protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free protocol with modified dosing
Study: 14627912
Drug: Historical matched
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical matched steroid-based control
Study: 10998732
Drug: Pharmacologic treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment, radiotherapy, and radioisotopes
Study: 8795448
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (30 p.p.m. for 15 min)
Study: 8795448
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (80 p.p.m. for 15 min)
Study: 8795448
Drug: Prolonged inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged inhalation of nitric oxide (30 p.p.m. for 55 min)
Study: 8795448
Drug: Aspirin (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (640 mg orally)
Study: 30554365
Drug: Glycerine iodine
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerine iodine 10% daily for 7 days
Study: 30554365
Drug: Neem seeds
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neem seeds extract (20% cream) daily for 10 days
Study: 30554365
Drug: Sumaq extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumaq extract (5% cream) daily for 10 days
Study: 28301614
Drug: HP lotion
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP lotion (halobetasol propionate 0.01%)
Study: 25297660
Drug: Patient-led titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-led titration
Study: 25297660
Drug: Physician-led titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-led titration
Study: 18654783
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Gd-DTPA (approximately 0.1 mmol/kg bw)
Study: 18654783
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of Gd-DTPA
Study: 17032158
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy plus treatment as usual (CBT plus TAU)
Study: 12937052
Drug: Dexamethasone administration
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administration (1993-1994 cohort)
Study: 12937052
Drug: Dexamethasone administration
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administration (2001 cohort)
Study: 10664926
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution (0.5%, 0.05 mL to each eye) with cimetidine (400 mg)
Study: 10664926
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution (0.5%, 0.05 mL to each eye)
Study: 8981292
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 50 mg daily
Study: 8981292
Drug: Modified-release dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release dipyridamole 400 mg daily